Payload Information

General Information of This Payload

Payload ID	PAY0IEFIL
Name	Temozolomide
Synonyms	Temozolomide; 85622-93-1; Methazolastone; Temodar; Temodal; Temozolamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; Sch 52365; CCRG-81045; Temozolomidum [Latin]; Temozolodida [Spanish]; Temozolomidum; CCRG 81045; NSC 362856; Sch-52365; Temozolodida; M&B 39831; M&B-39831; NSC-362856; temomedac; C6H6N6O2; CCRIS 8996; MB 39831; Temozolomide [INN:BAN]; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; M & B 39831; Temodal (TN); Temodar (TN); BRN 5547136; M-39831; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; NSC362856; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; CHEMBL810; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; UNII-YF1K15M17Y; MLS002701861; YF1K15M17Y; Temozolomide (JAN/USAN/INN); Temozolomide [USAN:INN:BAN]; DTXSID5043714; CHEBI:72564; Mk-7365; TMZ; NCGC00167429-01; 3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide; 8-CARBAMOYL-3-METHYLIMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE; DTXCID3023714; TMZ-Bioshuttle; 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide.; 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide; Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; SMR000466338; CAS-85622-93-1; Temozolomide, VETRANAL(TM), analytical standard; SR-01000759347; temozolomida; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide; Temozolomide Teva; Temozolomide Hexal; Temozolomide Sandoz; Temozolomide Hospira; MFCD00866492; Temozolomide- Bio-X; Temozolomide [BAN:INN]; TEMOZOLOMIDE [MI]; TEMOZOLOMIDE [INN]; TEMOZOLOMIDE [JAN]; D0C8EU; Essex brand of temozolomide; Temodar (TN) (Schering); TEMOZOLOMIDE [USAN]; SCHEMBL3739; 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide; Scheringbrand of temozolomide; TEMOZOLOMIDE [VANDF]; TEMOZOLOMIDE [MART.]; MLS000759447; MLS001424028; BIDD:GT0204; TEMOZOLOMIDE [USP-RS]; TEMOZOLOMIDE [WHO-DD]; GTPL7301; TEMOZOLOMIDE [EMA EPAR]; Temozolomide, >=98% (HPLC); BPEGJWRSRHCHSN-UHFFFAOYSA-N; HMS2051O12; HMS2090B08; HMS2232N13; HMS3264I14; HMS3269P05; HMS3372K13; HMS3393O12; HMS3413D06; HMS3654N05; HMS3677D06; HMS3713H16; Pharmakon1600-01502289; TEMOZOLOMIDE [ORANGE BOOK]; TEMOZOLOMIDE [EP MONOGRAPH]; 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; BCP03692; TEMOZOLOMIDE [USP MONOGRAPH]; Tox21_112433; AC-758; BDBM50034562; DL-190; NSC759883; s1237; Schering-Plough brand of temozolomide; STK623541; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo-[5,1-d][1,2,3,5]tetrazine-8-carboxamide; AKOS005557098; Tox21_112433_1; CCG-100870; CS-0943; DB00853; KS-1216; NC00120; NSC-759883; NCGC00167429-02; NCGC00167429-04; NCGC00167429-05; BP-25388; BT164447; HY-17364; LS-80558; NCI60_003316; BCP0726000154; M B 39831; Temozolomide 100 microg/mL in Acetonitrile; AM20110227; FT-0630936; FT-0674845; SW197500-4; T2744; D06067; EN300-122324; AB00639915-06; AB00639915-08; AB00639915-09; AB00639915_10; AB00639915_11; A841386; Q425088; Q-201786; SR-01000759347-4; SR-01000759347-5; BRD-K32107296-001-04-5; Z1201620684; 3-methyl-4-oxo-8-imidazo[5,1-d][1,2,3,5]tetrazinecarboxamide; Temozolomide, United States Pharmacopeia (USP) Reference Standard; 3-methyl-4-oxidanylidene-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-Methyl-8-aminocarbonyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one; Imidazo[5,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; {Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,} 3, 4-dihydro-3-methyl-4-oxo-; Temozolomide, Pharmaceutical Secondary Standard; Certified Reference Material; 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (Temozolomide); 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide(Temozolomide) Click to Show/Hide
Target(s)	Human Deoxyribonucleic acid (hDNA)			Target Info
Structure
Structure	3D MOL		2D MOL
Formula	C6H6N6O2
Isosmiles	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
PubChem CID	5394
InChI	InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
InChIKey	BPEGJWRSRHCHSN-UHFFFAOYSA-N
IUPAC Name	3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
Pharmaceutical Properties	Molecule Weight	194.15	Polar area	106
	Complexity	315	xlogp Value	-1.1
	Heavy Count	14	Rot Bonds	1
	Hbond acc	5	Hbond Donor	1

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	Hs 578T cells	Invasive breast carcinoma	CVCL_0332	[1]
Half Maximal Inhibitory Concentration (IC50)	100000	nM	Non-small cell lung cancer cells	Non-small cell lung cancer	Undisclosed	[2]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	PC-3 cells	Prostate carcinoma	CVCL_0035	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SN12C cells	Renal cell carcinoma	CVCL_1705	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SW620 cells	Colon adenocarcinoma	CVCL_0547	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	RPMI-8226 cells	Plasma cell myeloma	CVCL_0014	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	U-251MG cells	Astrocytoma	CVCL_0021	[1]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	U-251MG cells	Astrocytoma	CVCL_0021	[3]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SK-MEL-2 cells (MEK inhibitor-resistant)	Melanoma	CVCL_0069	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	COLO 205 cells	Colon adenocarcinoma	CVCL_0218	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	Caki-1 cells	Clear cell renal cell carcinoma	CVCL_0234	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	DLD-1 cells	Colon adenocarcinoma	CVCL_0248	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HCT 15 cells	Colon adenocarcinoma	CVCL_0292	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HT-29 cells	Colon adenocarcinoma	CVCL_0320	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	MDA-MB-435 cells	Amelanotic melanoma	CVCL_0417	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	NCI-H460 cells	Lung large cell carcinoma	CVCL_0459	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	OVCAR-3 cells (FZD7 overexpression)	Ovarian serous adenocarcinoma	CVCL_0465	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SK-MEL-28 cells (BRAF inhibitor resistant)	Cutaneous melanoma	CVCL_0526	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SK-MEL-5 cells	Cutaneous melanoma	CVCL_0527	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SNB-19 cells	Astrocytoma	CVCL_0535	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	T-47D cells	Invasive breast carcinoma	CVCL_0553	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	786-O cells	Renal cell carcinoma	CVCL_1051	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	DMS 114 cells	Lung small cell carcinoma	CVCL_1174	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	IGROV-1 cells	Ovarian endometrioid adenocarcinoma	CVCL_1304	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	NCI-ADR-RES cells	High grade ovarian serous adenocarcinoma	CVCL_1452	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	NCI-H226 cells	Pleural epithelioid mesothelioma	CVCL_1544	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	NCI-H23 cells	Lung adenocarcinoma	CVCL_1547	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	NCI-H322M cells	Minimally invasive lung adenocarcinoma	CVCL_1557	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	OVCAR-5 cells	Ovarian serous adenocarcinoma	CVCL_1628	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	OVCAR-8 cells	High grade ovarian serous adenocarcinoma	CVCL_1629	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SF539 cells	Gliosarcoma	CVCL_1691	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma	CVCL_0062	[1]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	NCI-H1299 cells (MMAE resistant)	Lung large cell carcinoma	CVCL_0060	[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SF268 cells	Astrocytoma	CVCL_1689	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[1]
Half Maximal Inhibitory Concentration (IC50)	100000	nM	NCI cells	Normal	Undisclosed	[2]
Half Maximal Inhibitory Concentration (IC50)	100000	nM	NCI cells	Normal	Undisclosed	[2]
Half Maximal Inhibitory Concentration (IC50)	100000	nM	NCI cells	Normal	Undisclosed	[2]
Tumor Growth Inhibition value (TGI)	>100000	nM	NCI cells	Normal	Undisclosed	[2]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	>100000	nM	Panel NCI-60 cells	Normal	Undisclosed	[5]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	MDA-MB-238 cells	Breast adenocarcinoma	Undisclosed	[4]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	SH-SY5Y cells	Bone marrow neuroblastoma	CVCL_0019	[3]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	ACHN cells	Renal adenocarcinoma	CVCL_1067	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	BT-549 cells	Breast ductal carcinoma	CVCL_1092	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	EKVX cells	Non-small cell lung carcinoma	CVCL_1195	[1]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	H4 cells	Neuroglioma	CVCL_1239	[3]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HCC 2998 cells	Colon adenocarcinoma	CVCL_1266	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HOP-62 cells	Non-small cell lung carcinoma	CVCL_1285	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HOP-92 cells	Non-small cell lung carcinoma	CVCL_1286	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	KM12 cells	Colon adenocarcinoma	CVCL_1331	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	M14 cells	Melanoma	CVCL_1395	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	Malme-3M cells	Melanoma	CVCL_1438	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	NCI-H522 cells	Non-small cell lung carcinoma	CVCL_1567	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	OVCAR-4 cells	Ovarian adenocarcinoma	CVCL_1627	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	RXF 393 cells	Renal carcinoma	CVCL_1673	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SF-295 cells	Glioblastoma	CVCL_1690	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SR cells	Leukemia	CVCL_1711	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	TK-10 cells	Renal carcinoma	CVCL_1773	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	UACC-257 cells	Melanoma	CVCL_1779	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	UACC-62 cells	Melanoma	CVCL_1780	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	MDA-N cells	Breast carcinoma	CVCL_1910	[1]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	WM 266-4 cells	Thigh metastasis of melanoma	CVCL_2765	[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	XF498 cells	Glioma	CVCL_8928	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	SNB-78 cells	Glioblastoma	CVCL_B321	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	M19-MEL cells	Melanoma	CVCL_B415	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	LXFL 529 cells	Non-small cell lung carcinoma	CVCL_D085	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	KM-20L2 cells	Colon carcinoma	CVCL_D889	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	100000	nM	HOP-18 cells	Non-small cell lung adenocarcinoma	CVCL_H642	[1]
Half Maximal Inhibitory Concentration (IC50)	>100000	nM	GL261 cells	Glioblastoma	CVCL_Y003	[6]
Half Maximal Inhibitory Concentration (IC50)	>1000000	nM	Astrocyte cells	Normal	Undisclosed	[7]
Half Maximal Inhibitory Concentration (IC50)	1000000	nM	MDCK cells	Normal	CVCL_0422	[8]
Half Maximal Inhibitory Concentration (IC50)	>1000000	nM	MDCK cells	Normal	CVCL_0422	[8]
Half Maximal Inhibitory Concentration (IC50)	>1000000	nM	MDCK cells	Normal	CVCL_0422	[8]
Half Maximal Inhibitory Concentration (IC50)	106700	nM	RG2 cells	Glioma	CVCL_3581	[9]
Half Maximal Inhibitory Concentration (IC50)	1100000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[10]
Half Maximal Inhibitory Concentration (IC50)	119300	nM	DBTRG-05MG cells	Anaplastic astrocytoma	CVCL_1169	[9]
Half Maximal Inhibitory Concentration (IC50)	120000	nM	MDA-MB-436 cells	Metastasis of ductal carcinoma	CVCL_0623	[11]
Half Maximal Inhibitory Concentration (IC50)	12740	nM	U-251MG cells	Astrocytoma	CVCL_0021	[12]
Half Maximal Inhibitory Concentration (IC50)	156100	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[13]
Half Maximal Inhibitory Concentration (IC50)	1720000	nM	WiDr cells	Colon adenocarcinoma	CVCL_2760	[14]
Half Maximal Inhibitory Concentration (IC50)	175000	nM	Raji cells	EBV-related Burkitt lymphoma	CVCL_0511	[15]
Half Maximal Inhibitory Concentration (IC50)	183000	nM	A2780 cells	Ovarian endometrioid adenocarcinoma	CVCL_0134	[16]
Half Maximal Inhibitory Concentration (IC50)	188000	nM	A2780 cells	Ovarian endometrioid adenocarcinoma	CVCL_0134	[16]
Half Maximal Inhibitory Concentration (IC50)	19380	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[17]
Half Maximal Inhibitory Concentration (IC50)	>19952.62	nM	Vero C1008 cells	Normal	CVCL_0574	[18]
Half Maximal Inhibitory Concentration (IC50)	>20000	nM	Vero C1008 cells	Normal	CVCL_0574	[18]
Half Maximal Effective Concentration (EC50)	>200000	nM	U-251MG cells	Astrocytoma	CVCL_0021	[19]
Half Maximal Inhibitory Concentration (IC50)	>200000	nM	U-251MG cells	Astrocytoma	CVCL_0021	[20]
Half Maximal Effective Concentration (EC50)	>200000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[19]
Half Maximal Inhibitory Concentration (IC50)	>200000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[20]
Half Maximal Inhibitory Concentration (IC50)	>200000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[21]
Half Maximal Inhibitory Concentration (IC50)	220000	nM	U-373MG ATCC cells	Astrocytoma	CVCL_2219	[22]
Half Maximal Inhibitory Concentration (IC50)	258000	nM	B16-F10 cells	Mouse melanoma	CVCL_0159	[22]
Half Maximal Inhibitory Concentration (IC50)	26000	nM	U-138MG cells	Astrocytoma	CVCL_0020	[23]
Half Maximal Inhibitory Concentration (IC50)	2898000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[24]
Half Maximal Inhibitory Concentration (IC50)	3.3	nM	KB cells	Human papillomavirus-related endocervical adenocarcinoma	CVCL_0372	[25]
Half Maximal Inhibitory Concentration (IC50)	>30000	nM	U-251MG cells	Astrocytoma	CVCL_0021	[26]
Half Maximal Inhibitory Concentration (IC50)	>30000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[26]
Half Maximal Inhibitory Concentration (IC50)	>30000	nM	C6 cells	Glioma	CVCL_0194	[26]
Half Maximal Inhibitory Concentration (IC50)	3186000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[24]
Half Maximal Inhibitory Concentration (IC50)	34000	nM	C6 cells	Glioma	CVCL_0194	[23]
Half Maximal Inhibitory Concentration (IC50)	343000	nM	COLO 205 cells	Colon adenocarcinoma	CVCL_0218	[27]
Half Maximal Inhibitory Concentration (IC50)	348200	nM	RG2 cells	Glioma	CVCL_3581	[9]
Half Maximal Inhibitory Concentration (IC50)	354700	nM	DBTRG-05MG cells	Anaplastic astrocytoma	CVCL_1169	[9]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	35700	nM	SNB-19 cells	Astrocytoma	CVCL_0535	[28]
Half Maximal Inhibitory Concentration (IC50)	36400	nM	U-251MG cells	Astrocytoma	CVCL_0021	[29]
Half Maximal Inhibitory Concentration (IC50)	36400	nM	U-251MG cells	Astrocytoma	CVCL_0021	[30]
Half Maximal Inhibitory Concentration (IC50)	366000	nM	A-431 cells	Skin squamous cell carcinoma	CVCL_0037	[31]
Half Maximal Inhibitory Concentration (IC50)	368000	nM	A2780 cells	Ovarian endometrioid adenocarcinoma	CVCL_0134	[16]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	369000	nM	U-373MG ATCC cells	Astrocytoma	CVCL_2219	[28]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	375000	nM	T98G cells	Glioblastoma	CVCL_0556	[32]
Half Maximal Inhibitory Concentration (IC50)	390000	nM	LN-18 cells	Glioblastoma	CVCL_0392	[7]
Half Maximal Inhibitory Concentration (IC50)	393000	nM	SH-SY5Y cells	Bone marrow neuroblastoma	CVCL_0019	[24]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	395000	nM	U-373MG ATCC cells	Astrocytoma	CVCL_2219	[5]
Half Maximal Inhibitory Concentration (IC50)	>40000	nM	A-172 cells	Glioblastoma	CVCL_0131	[4]
Half Maximal Inhibitory Concentration (IC50)	430600	nM	CTX TNA2 cells	Normal	CVCL_3670	[9]
Half Maximal Inhibitory Concentration (IC50)	4340	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[33]
Half Maximal Inhibitory Concentration (IC50)	455000	nM	U-251MG cells	Astrocytoma	CVCL_0021	[34]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	45600	nM	SNB-19 cells	Astrocytoma	CVCL_0535	[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	470000	nM	SNB-19 cells	Astrocytoma	CVCL_0535	[28]
Half Maximal Inhibitory Concentration (IC50)	486900	nM	CTX TNA2 cells	Normal	CVCL_3670	[9]
Half Maximal Inhibitory Concentration (IC50)	49000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[7]
Half Maximal Inhibitory Concentration (IC50)	5000	nM	TLX-5 cells	Lymphoma	CVCL_N032	[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	>50000	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[35]
Half Maximal Inhibitory Concentration (IC50)	>50000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[36]
Half Maximal Inhibitory Concentration (IC50)	>50000	nM	SH-SY5Y cells	Bone marrow neuroblastoma	CVCL_0019	[36]
Half Maximal Effective Concentration (EC50)	>50000	nM	BT142 cells	Oligoastrocytoma	CVCL_D718	[37]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	>500000	nM	DLD-1 cells	Colon adenocarcinoma	CVCL_0248	[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	>500000	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[5]
Half Maximal Inhibitory Concentration (IC50)	512620	nM	SH-SY5Y cells	Bone marrow neuroblastoma	CVCL_0019	[24]
Half Maximal Inhibitory Concentration (IC50)	525000	nM	A2780 cells	Ovarian endometrioid adenocarcinoma	CVCL_0134	[16]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	526000	nM	SNB-19 cells	Astrocytoma	CVCL_0535	[5]
Half Maximal Inhibitory Concentration (IC50)	570000	nM	T98G cells	Glioblastoma	CVCL_0556	[7]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	58748.94	nM	SK-OV-3 cells (FZD7 overexpression)	Ovarian serous cystadenocarcinoma	CVCL_0532	[1]
Half Maximal Inhibitory Concentration (IC50)	595000	nM	LoVo cells	Colon adenocarcinoma	CVCL_0399	[38]
Half Maximal Effective Concentration (EC50)	60460	nM	C6 cells	Glioma	CVCL_0194	[19]
Half Maximal Inhibitory Concentration (IC50)	60460	nM	C6 cells	Glioma	CVCL_0194	[20]
Half Maximal Inhibitory Concentration (IC50)	640000	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[10]
Half Maximal Inhibitory Concentration (IC50)	6426	nM	U-251MG cells	Astrocytoma	CVCL_0021	[12]
Half Maximal Inhibitory Concentration (IC50)	65000	nM	A-172 cells	Glioblastoma	CVCL_0131	[7]
Half Maximal Inhibitory Concentration (IC50)	666400	nM	CTX TNA2 cells	Normal	CVCL_3670	[9]
Half Maximal Inhibitory Concentration (IC50)	67810	nM	LN-229 cells	Glioblastoma	CVCL_0393	[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	68000	nM	U-373MG ATCC cells	Astrocytoma	CVCL_2219	[28]
Half Maximal Inhibitory Concentration (IC50)	69870	nM	SNB-19 cells	Astrocytoma	CVCL_0535	[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	70957.78	nM	SNB-75 cells	Glioblastoma	CVCL_1706	[1]
Half Maximal Inhibitory Concentration (IC50)	7284	nM	U-251MG cells	Astrocytoma	CVCL_0021	[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	72900	nM	U-373MG ATCC cells	Astrocytoma	CVCL_2219	[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	73960.53	nM	UO-31 cells	Renal carcinoma	CVCL_1911	[1]
Half Maximal Inhibitory Concentration (IC50)	>75000	nM	B16-F10 cells	Mouse melanoma	CVCL_0159	[40]
Half Maximal Inhibitory Concentration (IC50)	>75000	nM	B16-F10 cells	Mouse melanoma	CVCL_0159	[41]
Half Maximal Inhibitory Concentration (IC50)	>75000	nM	A375 cells	Amelanotic melanoma	CVCL_0132	[41]
Half Maximal Inhibitory Concentration (IC50)	>75000	nM	HaCaT cells	Normal	CVCL_0038	[41]
Half Maximal Inhibitory Concentration (IC50)	>75000	nM	MNT-1 cells	Melanoma	CVCL_5624	[41]
Half Maximal Inhibitory Concentration (IC50)	>75000	nM	MNT-1 cells	Melanoma	CVCL_5624	[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	75857.76	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[1]
Half Maximal Inhibitory Concentration (IC50)	7600	nM	GM892A cells	Normal	CVCL_H136	[15]
Half Maximal Inhibitory Concentration (IC50)	775000	nM	MDCK cells	Normal	CVCL_0422	[8]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	78342.96	nM	CCRF-CEM cells	T acute lymphoblastic leukemia	CVCL_0207	[1]
Half Maximal Inhibitory Concentration (IC50)	79000	nM	NCI cells	Normal	Undisclosed	[2]
Half Maximal Inhibitory Concentration (IC50)	800000	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	82035.15	nM	LOX IMVI cells	Melanoma	CVCL_1381	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	83560.3	nM	MOLT-4 cells	Adult T acute lymphoblastic leukemia	CVCL_0013	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	85506.67	nM	HL-60 cells	Adult acute myeloid leukemia	CVCL_0002	[1]
Half Maximal Inhibitory Concentration (IC50)	879000	nM	T98G cells	Glioblastoma	CVCL_0556	[22]
Half Maximal Inhibitory Concentration (IC50)	91000	nM	Carcinoma cells	Carcinoma	Undisclosed	[2]
Half Maximal Inhibitory Concentration (IC50)	93000	nM	NCI cells	Normal	Undisclosed	[2]
Half Maximal Inhibitory Concentration (IC50)	951000	nM	HT-29 cells	Colon adenocarcinoma	CVCL_0320	[27]
Half Maximal Inhibitory Concentration (IC50)	956000	nM	Hs 683 cells	Glioma	CVCL_0844	[22]
Half Maximal Inhibitory Concentration (IC50)	962500	nM	RG2 cells	Glioma	CVCL_3581	[9]
Half Maximal Inhibitory Concentration (IC50)	973900	nM	DBTRG-05MG cells	Anaplastic astrocytoma	CVCL_1169	[9]
Half Maximal Inhibitory Concentration (IC50)	98000	nM	NCI cells	Normal	Undisclosed	[2]
Half Maximal Inhibitory Concentration (IC50)	98000	nM	NCI cells	Normal	Undisclosed	[2]

Each Antibody-drug Conjugate Related to This Payload

References

Ref 1	PubChem BioAssay data set.
Ref 2	Synthesis and antitumor activity of methyltriazene prodrugs simultaneously releasing DNA-methylating agents and the antiresistance drug O(6)-benzylguanine. J Med Chem. 2004 Dec 30;47(27):6875-83. doi: 10.1021/jm049556d.
Ref 3	Phomanolides A and B from the Fungus Phoma sp.: Meroterpenoids Derived from a Putative Tropolonic Sesquiterpene via Hetero-Diels-Alder Reactions. J Nat Prod. 2015 Dec 24;78(12):3058-66. doi: 10.1021/acs.jnatprod.5b00969. Epub 2015 Dec 14.
Ref 4	Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene. Eur J Med Chem. 2021 Dec 5;225:113811. doi: 10.1016/j.ejmech.2021.113811. Epub 2021 Aug 31.
Ref 5	Antitumor imidazo[5,1-d]-1,2,3,5-tetrazines: compounds modified at the 3-position overcome resistance in human glioblastoma cell lines. Medchemcomm. 2016;7(12):2332-2343.
Ref 6	Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability. Eur J Med Chem. 2019 Jun 15;172:16-25. doi: 10.1016/j.ejmech.2019.03.048. Epub 2019 Mar 22.
Ref 7	New substituted 4H-chromenes as anticancer agents. Bioorg Med Chem Lett. 2012 Jul 1;22(13):4458-61. doi: 10.1016/j.bmcl.2012.04.074. Epub 2012 Apr 24.
Ref 8	New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. Eur J Med Chem. 2017 Feb 15;127:691-702. doi: 10.1016/j.ejmech.2016.10.037. Epub 2016 Oct 19.
Ref 9	Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression. J Nat Prod. 2020 Oct 23;83(10):3021-3029. doi: 10.1021/acs.jnatprod.0c00580. Epub 2020 Sep 22.
Ref 10	Boholamide A, an APD-Class, Hypoxia-Selective Cyclodepsipeptide. J Nat Prod. 2020 Apr 24;83(4):1249-1257. doi: 10.1021/acs.jnatprod.0c00038. Epub 2020 Mar 18.
Ref 11	Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold. Bioorg Med Chem Lett. 2014 Jan 15;24(2):462-6. doi: 10.1016/j.bmcl.2013.12.048. Epub 2013 Dec 18.
Ref 12	Enhanced pyrazolopyrimidinones cytotoxicity against glioblastoma cells activated by ROS-Generating cold atmospheric plasma. Eur J Med Chem. 2021 Nov 15;224:113736. doi: 10.1016/j.ejmech.2021.113736. Epub 2021 Aug 2.
Ref 13	Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3297-300. doi: 10.1016/s0960-894x(03)00553-5.
Ref 14	Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one. Eur J Med Chem. 2015;96:98-104. doi: 10.1016/j.ejmech.2015.04.004. Epub 2015 Apr 6.
Ref 15	Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem. 1995 Apr 28;38(9):1493-504. doi: 10.1021/jm00009a010.
Ref 16	Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J Med Chem. 2000 Nov 2;43(22):4084-97. doi: 10.1021/jm000950v.
Ref 17	Discovery of mitochondria-targeting berberine derivatives as the inhibitors of proliferation, invasion and migration against rat C6 and human U87 glioma cells. Medchemcomm. 2015;6(1):164-173.
Ref 18	Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity.
Ref 19	Efficient identification of novel anti-glioma lead compounds by machine learning models. Eur J Med Chem. 2020 Mar 1;189:111981. doi: 10.1016/j.ejmech.2019.111981. Epub 2019 Dec 19.
Ref 20	Bioactive triterpenoid saponins and phenolic compounds against glioma cells. Bioorg Med Chem Lett. 2014 Nov 15;24(22):5157-63. doi: 10.1016/j.bmcl.2014.09.087. Epub 2014 Oct 5.
Ref 21	Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides. Bioorg Med Chem Lett. 2021 Nov 1;51:128371. doi: 10.1016/j.bmcl.2021.128371. Epub 2021 Sep 15.
Ref 22	N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: screening, synthesis of simplified derivatives, and structure-activity relationship analysis. Eur J Med Chem. 2012 Aug;54:834-44. doi: 10.1016/j.ejmech.2012.06.050. Epub 2012 Jul 4.
Ref 23	Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species. Eur J Med Chem. 2012 Nov;57:268-74. doi: 10.1016/j.ejmech.2012.09.007. Epub 2012 Sep 12.
Ref 24	Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide. J Nat Prod. 2022 Jan 28;85(1):34-46. doi: 10.1021/acs.jnatprod.1c00595. Epub 2022 Jan 19.
Ref 25	Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents. J Med Chem. 2008 Dec 25;51(24):8163-7. doi: 10.1021/jm8008635.
Ref 26	Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression. Eur J Med Chem. 2022 Jan 5;227:113908. doi: 10.1016/j.ejmech.2021.113908. Epub 2021 Oct 8.
Ref 27	Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine. J Med Chem. 2000 Nov 2;43(22):4071-83. doi: 10.1021/jm000961o.
Ref 28	Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position. Medchemcomm. 2018 Jan 19;9(3):545-553. doi: 10.1039/c7md00554g. eCollection 2018 Mar 1.
Ref 29	Antcamphorols A-K, Cytotoxic and ROS Scavenging Triterpenoids from Antrodia camphorata. J Nat Prod. 2020 Jan 24;83(1):45-54. doi: 10.1021/acs.jnatprod.9b00580. Epub 2019 Dec 31.
Ref 30	Chemical modifications of ergostane-type triterpenoids from Antrodia camphorata and their cytotoxic activities. Bioorg Med Chem Lett. 2021 Jul 1;43:128066. doi: 10.1016/j.bmcl.2021.128066. Epub 2021 Apr 26.
Ref 31	Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. Eur J Med Chem. 2017 Aug 18;136:195-211. doi: 10.1016/j.ejmech.2017.05.016. Epub 2017 May 5.
Ref 32	Acridine-O(6)-benzylguanine hybrids: Synthesis, DNA binding, MGMT inhibition and antiproliferative activity. Eur J Med Chem. 2022 Jan 5;227:113909. doi: 10.1016/j.ejmech.2021.113909. Epub 2021 Oct 9.
Ref 33	Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. Bioorg Med Chem. 2009 Nov 1;17(21):7537-41. doi: 10.1016/j.bmc.2009.09.014. Epub 2009 Sep 15.
Ref 34	Chemical modifications of imidazole-containing alkoxyamines increase C-ON bond homolysis rate: Effects on their cytotoxic properties in glioblastoma cells. Bioorg Med Chem. 2019 May 15;27(10):1942-1951. doi: 10.1016/j.bmc.2019.03.029. Epub 2019 Mar 18.
Ref 35	New benzothieno[3,2-d]-1,2,3-triazines with antiproliferative activity: synthesis, spectroscopic studies, and biological activity. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3291-7. doi: 10.1016/j.bmcl.2014.06.007. Epub 2014 Jun 17.
Ref 36	Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents. Bioorg Med Chem Lett. 2018 Jul 15;28(13):2275-2278. doi: 10.1016/j.bmcl.2018.05.035. Epub 2018 May 17.
Ref 37	Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. J Med Chem. 2014 Oct 23;57(20):8307-18. doi: 10.1021/jm500660f. Epub 2014 Oct 1.
Ref 38	Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem. 2002 Nov 7;45(23):4961-74. doi: 10.1021/jm020259n.
Ref 39	Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment. J Med Chem. 2021 Aug 12;64(15):10908-10918. doi: 10.1021/acs.jmedchem.1c00277. Epub 2021 Jul 25.
Ref 40	The selective cytotoxicity of new triazene compounds to human melanoma cells. Bioorg Med Chem. 2017 Aug 1;25(15):3900-3910. doi: 10.1016/j.bmc.2017.04.049. Epub 2017 May 31.
Ref 41	Sulfur Analogues of Tyrosine in the Development of Triazene Hybrid Compounds: A New Strategy against Melanoma. ACS Med Chem Lett. 2021 Sep 2;12(11):1669-1677. doi: 10.1021/acsmedchemlett.1c00252. eCollection 2021 Nov 11.
Ref 42	Design and synthesis of a novel water soluble benzotetrazepinone. Bioorg Med Chem Lett. 2000 Oct 16;10(20):2325-7. doi: 10.1016/s0960-894x(00)00461-3.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.

Payload Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)